| Literature DB >> 35579269 |
Xiaoxuan Deng1, Maree Gould1, M Azam Ali1.
Abstract
Wound healing is a complex process that is critical in restoring the skin's barrier function. This process can be interrupted by numerous diseases resulting in chronic wounds that represent a major medical burden. Such wounds fail to follow the stages of healing and are often complicated by a pro-inflammatory milieu attributed to increased proteinases, hypoxia, and bacterial accumulation. The comprehensive treatment of chronic wounds is still regarded as a significant unmet medical need due to the complex symptoms caused by the metabolic disorder of the wound microenvironment. As a result, several advanced medical devices, such as wound dressings, wearable wound monitors, negative pressure wound therapy devices, and surgical sutures, have been developed to correct the chronic wound environment and achieve skin tissue regeneration. Most medical devices encompass a wide range of products containing natural (e.g., chitosan, keratin, casein, collagen, hyaluronic acid, alginate, and silk fibroin) and synthetic (e.g., polyvinyl alcohol, polyethylene glycol, poly[lactic-co-glycolic acid], polycaprolactone, polylactic acid) polymers, as well as bioactive molecules (e.g., chemical drugs, silver, growth factors, stem cells, and plant compounds). This review addresses these medical devices with a focus on biomaterials and applications, aiming to deliver a critical theoretical reference for further research on chronic wound healing.Entities:
Keywords: biomaterial; biomedical device; chronic wound; wound healing
Mesh:
Substances:
Year: 2022 PMID: 35579269 PMCID: PMC9544096 DOI: 10.1002/jbm.b.35086
Source DB: PubMed Journal: J Biomed Mater Res B Appl Biomater ISSN: 1552-4973 Impact factor: 3.405
FIGURE 1Schematic representation of the cutaneous wound healing. (A) Hemostasis. A wound causes blood clot formation. (B) Inflammation. Recruitment of macrophages and neutrophils. (C) Proliferation. Fibroblast proliferation induces epithelial cell generation. (D) Remodeling. Wound closure
FIGURE 2Functional group of curcumin structure in wound management
Hydrogels in wound management
| Materials | Crosslinking engine | Bioassay | Wound healing assay | Properties/results | References |
|---|---|---|---|---|---|
| GelMA | Chemical | — | In vitro | The cells were able to grow in each layer, which rendered epidermis‐like thin cell layers for keratin/chitosan nanofibers, and dermis‐like cell‐laden for the GelMA hydrogel. | [ |
| Sodium alginate/ gelatine/ AgNPs | Physical |
| In vitro/in vivo | AgNPs loaded sodium alginate/gelatine hydrogels accelerate skin tissue formation and stimulate early collagen scar generation in 14 days. | [ |
| Chitosan/ PEG/ AgNPs | Chemical |
| In vivo | AgNPs incorporated chitosan/PEG hydrogels exhibited sustained AgNPs release and achieved fast healing in the diabetic rabbit study. | [ |
| PEG/PAH/gold nanoparticles/poloxamer® 407 | — |
| In vivo | AuNPs with different shapes and surface modifications were loaded into PEG or PAH blended poloxamer® 407 hydrogels. AuNPs demonstrated slow release over 48 h. Hydrogels promoted skin re‐epithelization and achieved almost complete wound healing in 14 days. | [ |
| BAPEG/DCS/VEGF | Hybrid |
| In vitro/in vivo | BAPEG/DCS hybrid hydrogel repaired acute tissue immediately, due to adhesion and hemostasis of the hydrogel. Chronic wound healing could be achieved by VEGF‐loaded hydrogel. | [ |
| QCS‐C/PLEL | Physical |
| In vivo | An injectable adhesive thermo‐sensitive hydrogel was fabricated. In vivo study displayed superior ability to heal complicated skin defects compared with the suture and fibrin glue within 7 days. | [ |
| Chitosan/PVA/AgNPs | Physical |
| In vivo | AgNPs loaded chitosan/PVA hydrogel achieved 98 ± 4 to 99 ± 1% wound closure on day 12. | [ |
| Gelatine/quercetin/Carbopol® | — | — | In vivo | Quercetin loaded liposomal hydrogel showed a wound reduction of 98.93% on day 12. Whereas, simple liposome‐hydrogel achieved 52.26% wound closure on day 4. | [ |
| Chitosan/PLGA/PDGF/β‐glycerophosphate | — | — | In vivo | PDGF/PLGA hydrogel demonstrated better performance than PDGF alone in wound closure and granulation tissue formation. Moreover, autophagy levels were decreased in the PDGF/PLGA hydrogel group in comparison with control groups at day 8. | [ |
| Quaternized chitosan (QCS)/polydopamine‐coated reduction graphene oxide (rGO‐PDA)/ poly(N‐isopropylacrylamide) (PNIPAm) | Chemical |
| In vitro/in vivo | Self‐healing QCS/rGO3‐PDA/PNIPAm hydrogel with thermo‐responsive properties was successfully fabricated. The increased content of rGO‐PDA led to reduced drug release within 10 days, due to the decrease of swelling ratios. However, more drug (about 40%) were released in initial stage (8.5 h) with high rGO‐PDA loading. | [ |
| Ag/Ag@AgCl/ ZnO | Hybrid |
| In vivo | Ag/ Ag@AgCl/ ZnO hybrid hydrogel killed 95.95% E. coli and 98.49% S. aureus within 20 min. A sustained release of silver and zinc ions was observed in 21 days. Moreover, 90% Zn2+ was released in acidic conditions after 3 days, whereas, only 10% was released after 21 days in neutral conditions. | [ |
| PH/PVA | Physical | — | In vitro | PH/PVA hydrogel demonstrated higher swelling and cell proliferation rate compared to the PVA hydrogel after 1 and 5 days. | [ |
| BG/OSA | Chemical | — | In vivo | BG/OSA hydrogel completed the healing process on day 21 in a rat model. The presence of BG imparted tissue adhesiveness to the OSA hydrogel, due to alkaline ion release. | [ |
| PDA/PUE/PEG‐DA | Hybrid | — | In vivo | PEG‐DA/PDA/PUE hydrogel absorbed 2000 times more solution than its own weight and completed wound healing in a rat model in 20 days. | [ |
Abbreviations: AgNPs, silver nanoparticles; AuNPs, gold nanoparticles; BAPEG, benzaldehyde‐terminated PEG; BG, bioglass; DCS, dodecyl‐modified chitosan; GelMA, gelatine methacrylate; OSA, oxidized sodium alginate; PAH, polyallylamine hydrochloride; PDA, polydopamine; PDGF, platelet‐derived growth factor receptor; PEG, polyethylene glycol; PEG‐DA, polyethylene glycol diacrylate; PH, phlorotannins; PLEL, poly(d,l‐lactide)‐poly(ethylene glycol)‐poly(d,l‐lactide); PNIPAm, poly(N‐isopropylacrylamide; PUE, puerarin; PVA, Polyvinyl alcohol; QCS, quaternized chitosan; QCS‐C, catechol modified quaternized chitosan; rGO‐PDA, polydopamine‐coated reduction graphene oxide; VEGF, vascular endothelial growth factor.
FIGURE 3Hydrogel wound dressing production and application
Nanofibrous scaffolds in wound management
| Methods | Materials | Bioactive molecules | Flow rate (ml/h) | Voltage (kV) | Tip‐collector distance (cm) | Fiber diameter | Properties/results | Reference |
|---|---|---|---|---|---|---|---|---|
| Uniaxial electrospinning | PVA/keratin/chitosan | — | 0.4 | 16 | 10 | 120–151 nm | Nanofibrous scaffolds comprised of 5% w/v keratin and 2% w/v chitosan were successfully produced without deteriorating the nanofiber morphology. | [ |
| PVA/ GT/ MoS2 | TCH | 0.7 | 16 | 12 | 50–100 nm |
TCH loaded PVA/GT/MoS2/TCH nanofibers demonstrated excellent tensile strength and a slow release due to the presence of MoS2. Nanofibers exhibited non‐toxic effects on fibroblast cells and good antimicrobial activity against bacteria. | [ | |
| Silk fibroin | Fenugreek | 0.5 | 25 | 10 | 309 ± 83 nm | Fenugreek incorporated silk fibroin nanofiber was fabricated. Fenugreek release was 21.5 ± 0.9% in 24 h. | [ | |
| PCL | PCE | — | 18 | 15 | 212 ± 40–450 ± 100 nm | PCL/PCE hybrid nanofibrous matrix exhibited high antibacterial properties and similar tensile elastomeric modulus to human skin tissue. The water contact angle of pure PCL nanofibers was 130 ± 3°, and PCL‐30%PCE nanofibers were 41 ± 1°. | [ | |
| PCL/ Col I | — | 1 | 14 | — | Random (556.3 ± 36 nm), aligned (583.3 ± 55 nm), crossed (573.3 ± 91 nm) | PCL/Col I nanofibrous scaffolds were fabricated to resemble the organization of collagen fibrils in native skin. Diabetic rat models revealed the ability of scaffolds to enhance wound healing. | [ | |
| PCL/collagen | Bioactive glass nanoparticles | 10 μl/min | 15 | 1.4 | 300–500 nm | ECM‐biomimetic nanofibrous scaffolds were fabricated from the composition of PCL/collagen/bioactive glass for enhancing wound healing in diabetes. The wound recovery achieved 90% in 14 days. | [ | |
| Gelatine | Curcumin | 1.5 | 15 | 10 | — | Curcumin/gelatine‐blended nanofibrous mats were fabricated to enhance the bioavailability of curcumin for wound repair. Decreased wound area (2%) was seen at 15 days in a rat model. | [ | |
| Cellulose acetate/gelatine | Hydroxyapatite | 0.8 | 18 | 13 | 316 ± 115 nm |
Cellulose acetate/gelatine/hydroxyapatite nanocomposite mats were fabricated as wound dressings. The wound closure rate reached 66% in 7 days and 93% in 14 days. | [ | |
| PHB/ gelatine/ collagen | OSA | 1.5 | 1.5 | 12 | 80 ± 10 nm | PHB/ gelatine/ OSA nanofibers were coated with collagen for wound healing application. The degradation rate of the scaffolds was 71.8% in 12 h. | [ | |
| PCL | — | 0.1 | 21 | 6 | 250–3000 nm | An electrospun nanofibrous mat with a human skin pattern was successfully fabricated. In vitro cell culture had a proliferation of 7 days. | [ | |
| CA | — | 3 | 25 | 10 | 1.0 μm | Electrospun cellulose nanofiber mats demo high adsorption of multiple microorganisms. Uptake capacity of nanofiber mats collected 420 times more E. coli than control. | [ | |
| PCL | — | 1 | 18 | 15 | — | Electrospun PCL membranes fabricated as a skin substitute material. 5% PCL membrane had a modulus of 2.46 ± 0.26 MPa. Whereas, 15% PCL membrane was 3.84 ± 0.25 MPa. | [ | |
| Coaxial electrospinning | PCL (8 wt%)/gelatine (4 wt%) | Plant extracts/minocycline antibiotics | 1.2 | 13 | 12 | 302 ± 44 nm | PCL/gelatine nanofibrous mats with core‐shell structure containing antibiotics and natural extracts were fabricated with excellent antibacterial activities and enhanced proliferation of fibroblasts and keratinocytes. Higher keratinization was observed in the mat samples loaded with antibiotics and natural extracts. | [ |
| RSF | Curcumin/doxorubicin hydrochloride | 0.9 | 30 | 15 | 1224 nm | Dual drug loaded RSF nanofibers were fabricated. Curcumin and doxorubicin hydrochloride achieved a sustained release of 30% in 10 h. | [ | |
| PLGA/ GT | TCH | 1 and 0.2 | 15 | 15 | 180–460 nm | TCH‐loaded PLGA/GT nanofibers with a core‐shell structure exhibited excellent tensile strength in both dry and wet conditions, and a drug release of 20% in 2 h. | [ | |
| PCL/ Col I | DMOG | 5 and 10 μl/min | 15 | 15 | 200–500 nm | PCL/Col nanofibrous mats were fabricated and loaded with DMOG. Drug release for simply blended nanofibers was 53.3 ± 2.7% in 12 h. Whereas, core‐shell nanofibers achieved 17 ± 2.1% drug release in 12 h and 36.1 ± 4.2% in 24 h. | [ | |
| PLLA/ mesoporous silica nanoparticles | DMOG | 0.025 ml/min | 10 | 10 | — | PLLA/ mesoporous silica nanofibers loaded with DMOG were fabricated. The wound healing ratio was 97% in 15 days, and the cumulative release achieved 0.04 mg/mL in 12 days. | [ | |
| PCL | Ampicillin | 0.20–0.60 | 12–24 | 11 | 464 ± 214 nm | Ampicillin‐loaded AL‐BSA membranes were produced. The drug release rate reached 94.8% within 72 h. | [ | |
| PCL/zein | MNA | 0.7 to 1.4 | 23–25 | 18 | 0.6 ± 0.04 μm | MNA‐loaded PCL/zein coaxial nanofiber membranes were fabricated. The drug release rate was 12.2% in 2 h. | [ | |
| SA/ RCSPs | Calcium ions | — | 20 | 15 | 87.58 nm | SA/RCSPs/Calcium ions composite was fabricated based on the gelation reaction of calcium ions with alginate. The wound healing rate in the rat model was 46.6% on the 5th day and wound closure in 15 days. | [ | |
| Gelatine/ OC | — | 2 | 20–22 | 15–18 | 150–400 nm | Cellular nanofibers had a water contact angle of 80° and a swelling rate of 380%. | [ | |
| PCL/gelatine | — | 0.4–1.2 | 8–15 | — | 666 ± 164 nm | PCL/gelatine composite scaffolds were created and the wound closure rate in the animal model achieved 38% in 21 days. | [ | |
| PCL/ BC | — | 1–4 | 28–29.4 | 13 | 384.24 nm | PCL/BC composite nanofibers were able to regulate scaffold hydrophilicity, which significantly increased cell proliferation. 20%PCL/5%BC nanofibers demonstrated 100% cell viability in 72 h, same as control. | [ | |
| Triaxial electrospinning | PCL/cellulose acetate/ PVP | Nisin | 0.6, 1.2, and 0.2 | 12–14 | 20 | 0.8 μm |
Triaxial electrospun nisin‐containing membranes exhibited excellent antimicrobial properties for more than 5 days under damp conditions. Whereas, single blended nisin membranes immobilized nisin did not show antimicrobial activities. | [ |
| PCL/ gelatine | Doxycycline hydrophilic | 2–3 and 1–1.5 | 17–18 | 17–19 | 30.0 ± 17.0 μm | PCL/ gelatine fibers were electrospun into triaxial configuration. Doxycycline hydrophilic achieved controlled release, and the presence of GT allowed viable cells to attach to the fibers. | [ |
Abbreviations: BC, bacterial cellulose; CA, cellulose acetate; Col I, type I collagen; DMOG, dimethyloxalylglycine; GT, gum tragacanth; MNA, metronidazole; MoS2, molybdenum disulphide; OC, oleoyl chitosan; OSA, ostholamide; PCE, poly(citrate)‐ε‐polylysine; PCL, polycaprolactone; PHB, polyhydroxybutyrate; PLGA, poly(lactic‐co‐glycolic acid); PLLA, Poly‐L‐lactic acid; PVA, polyvinyl alcohol; PVP, Polyvinylpyrrolidone; RCSPs, Rana chensinensis skin peptides; RSF, regenerated silk fibroin; SA, sodium alginate; TCH, tetracycline.
FIGURE 4The nanofiber fabrication process for wound dressing manufacturing
FIGURE 5Illustration of negative pressure wound therapy
Surgical sutures in wound management
| Polymers | Absorbability | Bioactive molecules | Process technique | Duration of release/degradation | Type of analysis done | Properties/results | References |
|---|---|---|---|---|---|---|---|
| PCL/collagen | Absorbable | bFGF | Electrospinning | Over 21 days (bFGF release) | Morphology analysis, mechanical testing, growth factor release and in vivo study. | bFGF loading rate reached 33.3%, and PCL/collagen nanofibers were highly aligned, which offered a high surface area to improve mechanical strength. | [ |
| PDO | Non‐absorbable | Fibronectin | Dip‐coating | 24 h (fibronectin release) | Physicochemical testing, fibronectin release, in vitro cell culture and in vivo study. | Fibronectin‐coated suture reduced tissue drag, improved wound healing, and limited scar formation through enhanced re‐epithelialization. | [ |
| DAC | Absorbable | — | Wet spinning | 42 days (suture degradation) | Physicochemical testing, mechanical testing and in vivo study. | DAC suture had tensile strength for conventional suturing and significantly reduced wound healing time on a full‐thickness wound model. | [ |
| PLGA | — | mRNA | Dip‐coating | — | Physicochemical testing, mechanical testing, real‐time Quantitative PCR (qPCR,) in vitro cell culture and hemocompatibility testing. | mRNA‐PLGA coated suture did not affect cell viability and stimulated keratinocyte growth factor and functional fluorescent protein expression, which accelerated the wound healing process. | [ |
| Nylon (braided) | Non‐absorbable | Rifampicin/ trans‐resveratrol | Coating | 5 weeks (drug release) | Morphology analysis, mechanical testing, in vitro drug release, antimicrobial, and anti‐inflammatory testing. | Drug coated sutures achieved drug release within 5 weeks and demonstrated excellent antimicrobial and anti‐inflammatory properties. | [ |
| PCL (twisted) | Absorbable | Gentamicin/Ag | Electrospinning | Over 5 weeks (drug/silver release) | Morphology analysis, mechanical testing, in vitro drug/silver release, in vitro cell culture and antimicrobial testing | Drug/Ag‐coated PCL sutures had sustained release over 5 weeks after an initial burst and exhibited no influence on skin cell migration. Sutures inhibited bacterial growth rather than silver or drug alone loaded sutures. | [ |
| AASF | Non‐absorbable | AMOX | Soaking | 336 h (AMOX release) | In vitro drug release, antibacterial test, haemolysis assay, in vivo animal model | O2 plasma‐treated AASF sutures had an increase in drug loading to 16.7% and showed bacterial inhibition to S aureus and E coli. Sustained AMOX release was observed within 336 hours after a 24 h burst release. The addition of O2 plasma treatment and AMOX did not affect the hemocompatibility of AASF suture but reduced wound healing time. | [ |
| PP | Absorbable | Ag particles (3–5 wt%) | Grafting | — | Physicochemical testing, Morphology analysis, mechanical testing, antimicrobial test, cytocompatibility test | Radiation‐grafted and Ag‐loaded PP sutures demonstrated antimicrobial activity without adverse effects on cell viability. | [ |
| Fibrin | Absorbable | hMSCs |
Solution coextrusion | 1 week (hMSCs delivery) | hMSC attachment quantification, In vivo animal model. | Fibrin biological sutures were developed to deliver cells to infarcted tissue. 100,000 cells per suture seeded for 12–24 h. The authors were not confident in using hMSCs for regenerating contractile cardiomyocytes. |
[ |
| PP, PET, PDO, glycolic acid. | Non‐absorbable/ absorbable | Oxygen plasma | Coating | 60–90 days (suture degradation) | Morphology analysis, antimicrobial testing, tissue drag testing, mechanical testing, in vitro degradation, in vivo animal model. | Nanostructures were generated on the surface of commercial sutures via oxygen plasma treatment, which inhibited biofilm formation. | [ |
| PCL | Absorbable | Tadalafil | Electrospinning | 15 days (tadalafil release) | Morphology analysis, mechanical testing, in vitro drug release, in vivo animal model | Tadalafil loaded PCL suture demonstrated a sustained release, with no toxic effect on the systemic circulation. The number of blood vessels, fibroblast and epithelization significantly improved, which in turn enhanced the wound healing process. | [ |
| Polyglactin 910 | Absorbable | PDGF‐BB | Dip‐coating | 48 h (PDGF‐BB delivery) | In vitro PDGF‐BB release, in vivo animal model, in vivo uniaxial tensile biomechanical analysis |
PDGF‐BB coated commercial Vicryl sutures enhanced the remodeling phase in a rat model at 4 weeks following surgery. | [ |
| Polyglactin 910 | Absorbable | BMSC | Coating | — | In vivo animal model | BMSC coated commercial Vicryl sutures with stem cells attached to the surface, became unattached and migrated into the wound site to support soft tissue regeneration. | [ |
| Polyglactin 910/PLGA/PEG | Absorbable | Diclofenac sodium salt | Dip‐coating | 7 days (diclofenac release) | Physicochemical testing, Morphology analysis, in vitro drug release, in vitro cell culture, In vivo evaluation of anti‐inflammatory effects. | Diclofenac loaded PLGA nanoparticles with PEG and coated them onto commercial Vicryl suture surface. Diclofenac was released sustainably and significantly reduced the inflammatory reactions of tissues around the suture in the rat. | [ |
| PLLA (core)/PLGA (shell) | Absorbable | Aceclofenac (15%)/ insulin (4%) | Electrospinning |
10 days (aceclofenac release), 7 days (insulin release). 4 weeks (sheath degradation), 1 year (core degradation). | Morphological analysis, Mechanical testing, in vitro degradation study, in vitro drug release, in vitro cell culture, in vivo animal model. | Aceclofenac loaded PLLA/PLGA core‐shell structural sutures were released within 10 days and reduced inflammation reactions in the animal model. Insulin loaded PLLA/PLGA core‐shell structural sutures were released within 7 days and accelerated the wound healing process. | [ |
| Polyglactin 910 | Absorbable | Silver | Soaking | 21 days (silver release & suture degradation) | Physicochemical testing, Morphology analysis, in vitro degradation, in vitro silver release, antimicrobial test, in vitro cell culture, MTT assay, live/dead assay, scratch assay. | Silver coated polyglactin 910 sutures exhibited antibacterial activities and promoted cell migration and proliferation, which indicates its potential for facilitating wound healing. | [ |
| Fibrin | Absorbable | hMSCs | Solution coextrusion |
1–2 weeks (suture degradation) | In vitro live/dead cell viability assay, in vivo animal model, in vivo global mechanical function, in vivo cell delivery. | hMSCs incorporated fibrin biological sutures reduced fibrosis and enhanced mechanical properties. | [ |
| PCL (core)/PEG–PLA (sheath) | Absorbable | Curcumin | Electrospinning | 160 h (curcumin release) | Morphological analysis, mechanical testing, in vitro curcumin release. | Core‐sheath structured sutures had more drug release when the fibers had finer cores. The drug release time frame was controlled by adjusting the parameters of the electrospun process. | [ |
Abbreviations: AASF, Antheraea assama silk fibroin; Ag, silver; AMOX, amoxicillin trihydrate; BMSC, bone‐marrow‐derived mesenchymal stem cells; DAC, diacetyl chitin; hMSCs, human mesenchymal stem cells; mRNA, messenger ribonucleic acid; PCL, polycaprolactone; PDGF‐BB, platelet‐derived growth factor‐BB; PDO, polydioxanone; PEG, Polyethylene glycol; PET, poly(ethylene terephthalate); PLGA, poly(lactide‐co‐glycolide acid); PLLA, poly‐L‐lactic acid; PP, polypropylene.
FIGURE 6Bioactive molecule incorporated suture for wound management